MX2011013127A - Composiciones semi-solidas y productos farmaceuticos. - Google Patents

Composiciones semi-solidas y productos farmaceuticos.

Info

Publication number
MX2011013127A
MX2011013127A MX2011013127A MX2011013127A MX2011013127A MX 2011013127 A MX2011013127 A MX 2011013127A MX 2011013127 A MX2011013127 A MX 2011013127A MX 2011013127 A MX2011013127 A MX 2011013127A MX 2011013127 A MX2011013127 A MX 2011013127A
Authority
MX
Mexico
Prior art keywords
semi
pharmaceutical products
solid compositions
cancerous conditions
pdt
Prior art date
Application number
MX2011013127A
Other languages
English (en)
Inventor
Gry Stensrud
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of MX2011013127A publication Critical patent/MX2011013127A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Esta invención se refiere a composiciones semisólidas y a productos farmacéuticos semi-sólidos para su uso en el tratamiento fotodinámico (PDT, por sus siglas en Inglés) del cáncer, de las afecciones precancerosas y de las afecciones no cancerosas en el sistema reproductor femenino, en el ano y en el pene, preferentemente para su uso en PDT de la displasia endometrial, cervical, vulvar, vaginal, anal y peneal y a las infecciones provocadas por VPH del útero, el cérvix, la vulva, la vagina, el ano y el pene. Las composiciones semi-sólidas y los productos farmacéuticos comprenden un ingrediente activo que es el ácido 5-aminolevulínico (5-ALA) o un precursor o un derivado de 5-ALA o las sales de los mismos farmacéuticamente aceptables. La invención se refiere además a los métodos de PDT del cáncer, las afecciones pre-cancerosas y las afecciones no cancerosas en el sistema reproductor femenino, el ano y el pene, en donde las composiciones semi-sólidas y los productos farmacéuticos son utilizados.
MX2011013127A 2009-06-11 2010-06-11 Composiciones semi-solidas y productos farmaceuticos. MX2011013127A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09251537 2009-06-11
PCT/EP2010/003532 WO2010142457A1 (en) 2009-06-11 2010-06-11 Semi-solid compositions and pharmaceutical products

Publications (1)

Publication Number Publication Date
MX2011013127A true MX2011013127A (es) 2012-02-21

Family

ID=41213323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013127A MX2011013127A (es) 2009-06-11 2010-06-11 Composiciones semi-solidas y productos farmaceuticos.

Country Status (21)

Country Link
US (2) US20120136055A1 (es)
EP (2) EP2440199B1 (es)
JP (1) JP5840604B2 (es)
KR (2) KR101797780B1 (es)
CN (1) CN102458388B (es)
AU (1) AU2010257753B2 (es)
BR (1) BRPI1010761A2 (es)
CA (1) CA2763923C (es)
CL (1) CL2011003094A1 (es)
DK (1) DK2440199T3 (es)
ES (2) ES2821831T3 (es)
HK (1) HK1164163A1 (es)
HU (1) HUE026911T2 (es)
MX (1) MX2011013127A (es)
NZ (1) NZ596943A (es)
PL (1) PL2440199T3 (es)
RU (1) RU2526803C2 (es)
SG (1) SG176688A1 (es)
SI (1) SI2440199T1 (es)
WO (1) WO2010142457A1 (es)
ZA (1) ZA201109126B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521251A (ja) 2010-03-01 2013-06-10 フォトキュア エイエスエイ 美容組成物
EP2590714B1 (en) 2010-07-09 2017-03-08 Photocure ASA Devices containing dry compositions for use in photodynamic therapy
KR102057349B1 (ko) 2011-12-19 2019-12-18 포토큐어 에이에스에이 광 조사 기구
CN102670577B (zh) * 2012-05-18 2018-04-13 上海复旦张江生物医药股份有限公司 一种光敏剂组合物、其使用方法及用途
US20140067024A1 (en) 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
GB201221123D0 (en) 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
KR101768843B1 (ko) * 2013-02-28 2017-08-17 미라 파마 코포레이션 주사가능 장기-작용 국소 마취제 반고체 제형 및 이의 조성물
GB201306369D0 (en) 2013-04-09 2013-05-22 Photocure As Irradiation device
EP3760186A1 (en) * 2014-04-30 2021-01-06 Allergan, Inc. Formulations of biologics for intravesical instillation
CZ307444B6 (cs) * 2015-04-22 2018-08-29 Jakub Rak Mukoadhezivní polymerní film pro fotosenzitivní terapii v ústní dutině s obsahem fotosenzitizérů
ES2910034T3 (es) 2015-12-17 2022-05-11 Photocure Asa Procedimiento de fototerapia dinámica (FTD) para el cáncer de vejiga
GB201522309D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
GB201522398D0 (en) 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
CA3017432A1 (en) * 2016-03-28 2017-10-05 Vidac Pharma Ltd. Stable pharmaceutical compositions for topical administration and uses thereof
US11884784B2 (en) 2016-05-10 2024-01-30 North Carolina State University Photodynamic compositions, methods of making, and uses thereof
WO2017196961A1 (en) * 2016-05-10 2017-11-16 North Carolina State University Photodynamic compositions, methods of making, and uses thereof
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
CN110573395B (zh) * 2017-05-01 2023-09-12 康明斯有限公司 用于控制混合动力系统中能量产生的系统和方法
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
GB201808571D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
EP4349401A1 (en) 2019-02-13 2024-04-10 Alpheus Medical, Inc. Non-invasive sonodynamic therapy
CN110575612A (zh) * 2019-09-27 2019-12-17 赵志国 女用光动力凝胶封包敷料装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5234957A (en) * 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
CA2158724A1 (en) * 1994-09-20 1996-03-21 Jue-Chen Liu Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
HU225148B1 (en) 1995-03-10 2006-07-28 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy or diagnosis, products and kits comprising thereof and method of in vitro diagnosis by their using
EP0844876A4 (en) * 1995-08-14 1999-12-01 Univ California ENDOMETRIAL ABLATION USING PHOTODYNAMIC TREATMENT WITH GREEN PORPHYRINS
DE10003620A1 (de) * 2000-01-28 2001-08-02 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
US20020132035A1 (en) * 2001-01-10 2002-09-19 Dov Tamarkin Synthetic fat composition
GB0018527D0 (en) 2000-07-27 2000-09-13 Photocure Asa Composition
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0118251D0 (en) 2001-07-26 2001-09-19 Photocure Asa Method
US7264629B2 (en) * 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
EP1312353A1 (en) 2001-11-16 2003-05-21 Ecole Polytechnique Federale De Lausanne (Epfl) Method for hair removal
US20040009212A1 (en) * 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
CA2457214A1 (en) * 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
GB0424833D0 (en) 2004-11-10 2004-12-15 Photocure Asa Method
DE102005019628A1 (de) * 2005-04-26 2006-11-09 Technische Universität Braunschweig Formulierung zur dermalen Anwendung
GB0700580D0 (en) * 2007-01-11 2007-02-21 Photocure Asa Use
GB0724279D0 (en) 2007-12-12 2008-01-23 Photocure Asa Use
GB0900461D0 (en) 2009-01-12 2009-02-11 Photocure Asa Photodynamic therapy device

Also Published As

Publication number Publication date
CA2763923C (en) 2016-09-13
RU2526803C2 (ru) 2014-08-27
ES2573085T3 (es) 2016-06-06
CL2011003094A1 (es) 2012-07-20
NZ596943A (en) 2013-09-27
EP2440199A1 (en) 2012-04-18
SG176688A1 (en) 2012-01-30
US9326964B2 (en) 2016-05-03
HK1164163A1 (zh) 2012-09-21
EP2440199B1 (en) 2016-04-13
ZA201109126B (en) 2013-02-27
EP3042647A1 (en) 2016-07-13
HUE026911T2 (en) 2016-07-28
WO2010142457A1 (en) 2010-12-16
BRPI1010761A2 (pt) 2016-03-22
CA2763923A1 (en) 2010-12-16
PL2440199T3 (pl) 2016-10-31
KR20170116198A (ko) 2017-10-18
DK2440199T3 (en) 2016-05-17
AU2010257753B2 (en) 2014-09-18
KR101797780B1 (ko) 2017-11-14
RU2011150919A (ru) 2013-07-20
EP3042647B1 (en) 2020-08-26
JP2012529452A (ja) 2012-11-22
JP5840604B2 (ja) 2016-01-06
US20120136055A1 (en) 2012-05-31
ES2821831T3 (es) 2021-04-27
US20150238457A1 (en) 2015-08-27
AU2010257753A1 (en) 2012-01-12
KR20120046155A (ko) 2012-05-09
CN102458388B (zh) 2016-09-28
CN102458388A (zh) 2012-05-16
SI2440199T1 (sl) 2016-05-31

Similar Documents

Publication Publication Date Title
MX2011013127A (es) Composiciones semi-solidas y productos farmaceuticos.
UY31475A1 (es) Sistema de administracion vaginal
JP2012529452A5 (es)
HK1077524A1 (en) Creation of tissue engineered female reproductive organs
NZ600028A (en) Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis
Garozzo et al. Büschke–Lowenstein tumour in pregnancy
ES2574999T3 (es) Método para la contracepción a demanda usando levonorgestrel o norgestrel
RU2341258C1 (ru) Комплексный способ лечения остроконечных кондилом аногенитальной локализации
CN201346354Y (zh) 妇科用阴道给药器
MX2011002098A (es) Formulacion de la sal acido glicirricinico en gel termorreversible y acido tricloroacetico como queratolitico, para su aplicacion en el tracto genital de mujeres y varones con lesiones causadas por el virus del papiloma humano y en el cancer de los mismos.
KR20080041716A (ko) 피부 병변을 치료하기 위한 히드라존 제제
Hildebrandt et al. A non-surgical uterine lavage technique in large cats intended for treatment of uterine infection-induced infertility
Soumya et al. A brief assessment on cervical cancer
Nazac et al. Neoplasias intraepiteliales de la vulva
Mitichkin et al. Surgical correction of recurrent genital prolapse
Sidorova et al. The effects of new pharmaceutical composition containing Epigallocatechin-3-Gallate (EGCG) to inhibit methylation of the tumor supressor genes in patients with cervical intraepithelial neoplasia
WO2008013602A3 (en) Apparatus and methods for uterine anesthesia
Newaj Genital warts: what are our options?: sexual health
Hollingworth Vulval Swellings
Zaidi et al. Cutaneous Manifestations of Diseases of the External Genitalia
HRP20151176T1 (hr) Nifuratel-sulfoksid, namijenjen upotrebi u lijeäśenju bakterijskih infekcija
Potter Lichen sclerosus: case report
Benchohra et al. Vaginal and Rectal Prolapse (Type II) in Montbeliarde Dairy Cow-Case Report
Olsen et al. Update on diagnosis, treatment, and prevention of genital human papillomavirus manifestations
Van Rensburg Adolescents-dysmenorrhoea: family focus